. Author manuscript; available in PMC: 2012 Sep 1.

Published in final edited form as: J Hepatol. 2010 Dec 21;55(3):654–659. doi: 10.1016/j.jhep.2010.11.021

Table 1.

Baseline patient characteristics and selected clinical data of patients (n=1022)

	Microvesicular Steatosis
	Present (n=102)	Absent (n=920)	p-value^®
Age at enrollment (yrs)	50.2 ±12.5	49.5 ± 11.9	0.4
Females (%)	66	63	0.6
Caucasians (%)	88	84	0.5
BMI (kg/m²)^€	36.1 ± 7.6	34.4 ±6.4	0.1
Diabetes (%)	24.5	29.5	0.3
HOMA–IR^†	4.4 (3.4–5.9)	4.0 (2.6–6.3)	0.3
AST (U/L)^*	50 (36–71)	45 (32–65)	0.07
ALT (U/L)^*	63 (46–102)	65 (43–97)	0.6

Values with age, gender, race, and BMI are expressed as mean with standard deviation.

^†

HOMA-IR: Homeostatic model assessment for Insulin resistance, only non-diabetic patients with insulin and glucose measurements within 6 months of liver biopsy were included (n=505).

IQR- median interquartile ranges of AST and ALT values obtained within 6 months of liver biopsy (n=650).

^€

Only patients with height and weight measurements within 6 months of the liver biopsy were included (n=636).

^®

P-values derived from chi-square tests (gender, diabetes), Fisher’s Exact Test (race), and Wilcoxon rank sum test for continuous variables.